

PHARMACEUTICAL 2023

Eliem Therapeutics Inc. Rank 41 of 446







RealRate

Eliem Therapeutics Inc. Rank 41 of 446

The relative strengths and weaknesses of Eliem Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Eliem Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 100% points. The greatest weakness of Eliem Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 249%, being 206% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	134,393
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,097
Liabilities, Non-Current	180
Other Assets	599
Other Compr. Net Income	-235
Other Expenses	0
Other Liabilities	0
Other Net Income	-109
Other Revenues	0
Property and Equipment	0
Research and Development	26,214
Selling, General and Administrative Expense	18,921

Output Variable	Value in 1000 USD
Assets	134,992
Liabilities	6,277
Expenses	45,135
Revenues	0
Stockholders Equity	128,715
Net Income	-45,244
Comprehensive Net Income	-45,362
Economic Capital Ratio	249%

